Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

268.17 USD +2.44 (+0.92%)
Official Closing Price Updated: 5:52 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 874,100
Open 265.73
Bid (Size) 264.00 (1)
Ask (Size) 268.17 (7)
Prev. Close 265.73
Today's Range 263.50 - 268.59
52wk Range 223.25 - 363.92
Shares Outstanding 211,007,945
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biogen Announces Two New Nominees for Election to Board of Directors
From GlobeNewswire News Releases
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
From GlobeNewswire News Releases

Performance

YTD
+10.38%
+10.38%
1 Month
+0.77%
+0.77%
3 Month
+0.24%
+0.24%
6 Month
-8.00%
-8.00%
1 Year
-16.96%
-16.96%

More News

Read More
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
From GlobeNewswire News Releases
Top Health Care Stocks Worth Investing In Now? 4 In Focus
Tags Market News
From StockMarket.com
Noteworthy Friday Option Activity: JNJ, BIIB, BBY
Tags Stocks
From Market News Video
Week in Review: Sorrento Acquires ACEA in $488 Million Deal between Two San Diego-China Oncology Biopharmas
From ChinaBio® Today
3 Biotech Stocks With Big Catalysts Around the Corner
Tags BIIB JNJ NVAX
From Motley Fool
Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis
Tags Benzinga News Phase 3 Trial
From Benzinga
Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over
From Investor's Business Daily
Biotech Stocks Could Use A Win — Will The First Quarter Offer That?
From Investor's Business Daily
Biogen Acquires Rights to Bio-Thera RA Biosimilar for $30 Million Upfront
From ChinaBio® Today
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.